Abstract
Safety and cardiovascular effectiveness of bempedoic acid remains uncertain. Ten randomized control trials were selected using Pubmed and Embase through October 2019. The clinical endpoints included major adverse cardiovascular outcomes (MACE), serious adverse events, muscle related adverse events
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
